Vivozon's Oral Non-Opioid Analgesic Candidate Granted South Korean Patent

[Financial News] Vivozon, an affiliate of Vivozon Pharmaceutical, has received approval for a South Korean patent for its oral non-opioid analgesic candidate VVZ-2471. It has also completed patent registration in the State of Israel, expanding the regions where it has secured global intellectual property rights.
According to Vivozon Pharmaceutical on the 21st, the South Korean patent is notable for broadly recognizing rights to the core compound group, including VVZ-2471. With claims covering the 125 compounds listed at the time of the patent application recognized, Vivozon secured domestic rights to VVZ-2471 and related candidates.
Vivozon has secured patents in South Korea and the State of Israel, following the United States, China, Taiwan, the Republic of South Africa, Japan and Europe. The number of countries and regions where it has secured the relevant patent rights has therefore risen to eight. Patent examinations are currently underway in Australia, Brazil, Canada and India.
VVZ-2471 is an oral non-opioid analgesic candidate that simultaneously inhibits two receptors involved in pain signal transmission: the mGluR5 receptor and the 5-HT2A receptor. It is being developed with the aim of reducing the addiction and tolerance issues that may arise with opioid-class drugs.
Clinical development is also underway. In South Korea, dosing in a Phase 2 clinical trial involving patients with postherpetic neuralgia (PHN) was recently completed. In the United States, an investigator-initiated trial (IIT) is being conducted with local research institutions following approval of an investigational new drug (IND) application.
A Vivozon official said, "By securing patent rights successively in South Korea and the State of Israel, we have strengthened VVZ-2471's global intellectual property foundation. We will move ahead in earnest with global commercialization by carrying out the domestic Phase 2 trial and the investigator-initiated trial in the United States without disruption."
[email protected] Jung Sang-hee Reporter